Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Sep;97(37):e12172.
doi: 10.1097/MD.0000000000012172.

Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis

Li Ren  1 , Jie Yi, Jing Yang, Peng Li, Xueyan Cheng, Peixian Mao
Affiliations
Meta-Analysis

Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis

Li Ren et al. Medicine (Baltimore). 2018 Sep.

Abstract

Previous studies have indicated that nonsteroidal anti-inflammatory drugs (NSAIDs) use is associated with Parkinson disease risk, but presented controversial results.Medline, Embase, Web of Science, and the Cochrane Database were searched update to November 2017. Key data were extracted from eligible studies. A dose-response meta-analysis was conducted for synthesizing data from eligible studies.Fifteen eligible studies were included in this meta-analysis. NSAIDs use was not associated with Parkinson disease risk [relevant risk (RR): 0.06; 95% confidence interval (95% CI), 0.91-1.02]. Subgroup analysis showed that aspirin use (RR: 1.14; 95% CI, 0.98-1.30) or ibuprofen use (RR: 1.01; 95% CI, 0.88-1.17) was not associated with Parkinson disease risk; however, the use of non-aspirin NSAIDs was significantly associated with Parkinson disease risk (RR:0.91; 95% CI, 0.84-0.99). Furthermore, NSAIDs use was not associated with the risk of Parkinson disease in female (RR: 0.99; 95% CI, 0.83-1.17) and male (RR: 1.01; 95% CI, 0.88-1.16). In addition, a dose-response showed per 1 number of prescription incremental increase in NSAIDs use was not associated with the risk of Parkinson disease (RR: 0.96; 95% CI, 0.91-1.02), per 1 year of duration of NSAIDs use incremental increase was not associated with the risk of Parkinson disease (RR: 0.98; 95% CI, 0.92-1.03), and per 1 dosage of NSAIDs use incremental increase was not associated with the risk of Parkinson disease (RR: 0.98; 95% CI, 0.95-1.02).NSAIDs use was not associated with the risk of Parkinson disease. The potency and the cumulative NSAIDs use did not play critical roles.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
Dose–response relationship between number of prescription NSAIDs use in relation to risk of Parkinson disease.
Figure 3
Figure 3
Dose–response relationship between duration of NSAIDs use in relation to risk of Parkinson disease.
Figure 4
Figure 4
Dose–response relationship between dosage of NSAIDs use in relation to risk of Parkinson disease.
See this image and copyright information in PMC

References

    1. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 2016;15:1257–72. - PubMed
    1. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001;39:167–74. - PubMed
    1. Hirsch E, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382–97. - PubMed
    1. Hunot S, Hirsch E. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;(53 suppl 3):S49–58. discussion S58-S60. - PubMed
    1. Lanas A, Hirschowitz B. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999;11:375–81. - PubMed

Publication types

MeSH terms

Substances